Related Experiment Video

Updated: Jun 16, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

CD73 blockade alleviates collagen-induced arthritis by inhibiting synovial fibroblast activity

Xia-Nan Wu1, Rui-Cheng Li1, Ruo-Xuan Hei1

  • 1Department of Clinical Laboratory, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.

Iranian Journal of Basic Medical Sciences
|June 15, 2026
PubMed
Abstract

Insights

Blocking CD73 significantly reduced rheumatoid arthritis (RA) progression by inhibiting synovial fibroblast activity. CD73 blockade offers a promising therapeutic strategy for RA patients, targeting inflammation and joint destruction.

Area of Science:

  • Immunology
  • Rheumatology
  • Molecular Biology

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by progressive cartilage erosion and joint destruction.
  • CD73 is recognized for its crucial role in modulating inflammatory responses within the immune system.

Purpose of the Study:

  • To investigate the therapeutic effects of CD73 blockade on rheumatoid arthritis progression.
  • To elucidate the underlying mechanisms by which CD73 blockade impacts RA pathogenesis.

Main Methods:

  • Quantified soluble CD73 levels using ELISA and detected tissue expression via immunohistochemistry.
  • Utilized a collagen-induced arthritis (CIA) rat model to assess CD73 inhibitor efficacy in vivo.
  • Evaluated synovial inflammation, cartilage erosion, and bone destruction using histological staining and Micro-CT.

Main Results:

  • CD73 expression was elevated in RA patients' synovial tissues and serum, potentially linked to hypoxia via the hypoxia-inducible factor pathway.
  • CD73 blockade in CIA rats effectively reduced synovial inflammation, bone destruction, and synovioblast proliferation and invasion.
  • Transcriptome analysis indicated CD73 blockade modulated inflammatory responses, neutrophil chemotaxis, and integrin-mediated signaling pathways.

Conclusions:

  • CD73 blockade demonstrates therapeutic potential in alleviating RA progression by regulating synovial fibroblast activity.
  • Targeting CD73 presents a viable therapeutic strategy for managing rheumatoid arthritis.
Keywords:
Bone destructionCD73Rheumatoid arthritisSynovial fibroblastsSynovial inflammation

More Related Videos

A Cryo-pulverization Protocol for Processing Mouse Paws to Evaluate Molecular Pathways of Tissue Inflammation in a Collagen Induced Arthritis Model11:03

A Cryo-pulverization Protocol for Processing Mouse Paws to Evaluate Molecular Pathways of Tissue Inflammation in a Collagen Induced Arthritis Model

Published on: October 30, 2019

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...